<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343233">
  <stage>Registered</stage>
  <submitdate>22/07/2011</submitdate>
  <approvaldate>22/07/2011</approvaldate>
  <actrnumber>ACTRN12611000775910</actrnumber>
  <trial_identification>
    <studytitle>A trial to evaluate the effects of different monosaccharide preloads on incretin hormone secretion, gastric emptying and post-meal blood glucose in healthy subjects and patients with type 2 diabetes mellitus.</studytitle>
    <scientifictitle>A randomised placebo controlled crossover trial to evaluate the effects of different monosaccharide preloads on incretin hormone secretion, gastric emptying and postprandial glycaemia in healthy subjects and patients with type 2 diabetes mellitus.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Each subject will undergo four studies, in which they will receive a sweet "preload" drink, containing either 40g glucose, 40g 3-O-methylglucose, 40g Tagatesse, or 60mg sucralose (placebo control) in double-blind, randomised fashion, separated by 3 - 7 days, consumed between T=-22 to -20 min, before a mashed potato meal consumed between T=-5 to 0 min.</interventions>
    <comparator>60mg sucralose drink</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma GLP-1 concentration</outcome>
      <timepoint>T=-25, -10, 0, 15, 30, 60, 90, 120, and 240 min</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood glucose concentration</outcome>
      <timepoint>T=-25, -10, 0, 15, 30, 60, 90, 120, and 240 min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gastric half-emptying time measured by breath test after labelling the potato meal with 13C octanoic acid</outcome>
      <timepoint>Breath samples at immediately before the potato meal and then every 5 min for the first hour after, then every 15 min for a further 3 hours.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sensations of hunger and fullness by visual analog scales</outcome>
      <timepoint>T=-25, -10, 0, 15, 30, 60, 90, 120, and 240 min</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers and patients with type 2 diabetes mellitus</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Medications affecting gut function; Alcohol intake &gt;20g daily or cigarette smoking; Significant gastrointestinal disease or surgery; Impaired liver or renal function; Blood donation within 3 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers</concealment>
    <sequence>computer-generated random number table</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>24/02/2010</anticipatedstartdate>
    <actualstartdate>24/02/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>3/05/2010</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital</primarysponsorname>
    <primarysponsoraddress>North Terrace Adelaide South Australia 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>National Health and Medical Research Council GPO Box 1421 Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will evaluate the effects of different sugars on the release of the incretin hormone GLP-1 from the small intestine, and how this affects the gastric emptying of, and glycaemic response to, a subsequent meal, in both healthy subjects and patients with type 2 diabetes.</summary>
    <trialwebsite />
    <publication>Wu T, Zhao BR, Bound MJ, Checklin HL, Bellon M, Little TJ, Young RL, Jones KL, Horowitz M, Rayner CK. Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans. Am J Clin Nutr. 2012 Jan;95(1):78-83</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 3, Hanson Institute Royal Adelaide Hospital, North Terrace, Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>22/10/2009</ethicapprovaldate>
      <hrec>RAH protocol no. 091014</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chris Rayner</name>
      <address>Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>